The antileukaemic tyrosine kinase inhibitor, imatinib, has been reported to inhibit specifically the growth of bcr-abl expressing CML progenitors at levels of 0.1-5.0 lM, by blocking the ATP-binding site of the kinase domain of bcr-abl. Inhibition of the c-abl, platelet-derived growth factor receptor and stem cell factor receptor (c-kit) tyrosine kinases by imatinib has also been reported. Here, we demonstrate that imatinib significantly inhibits in vitro monocyte/macrophage development from normal bone marrow progenitors, while neutrophil and eosinophil development was less affected. Monocyte/ macrophage inhibition was observed in semisolid agar and liquid cultures at concentrations of imatinib as low as 0.3 lM. The maturation of monocytes into macrophages was also found to be impaired following treatment of cultures with 1.0 lM imatinib. Imatinib blocked monocyte/ macrophage development in cultures stimulated with and without M-CSF, suggesting that inhibition of the M-CSF receptor, c-fms, by imatinib was unlikely to be responsible. Imatinib may therefore have an inhibitory activity for other kinase(s) that play a role in monocyte/macrophage differentiation. This inhibition of normal monocyte/macrophage development was observed at concentrations of imatinib achievable pharmacologically, suggesting that imatinib or closely related derivatives may have potential for the treatment of diseases where monocytes/macrophages contribute to pathogenesis.
Introduction
Cell differentiation is the highly regulated process by which cells assume specialised functions and morphologies, and generally involves a change from a primitive progenitor cell to a mature cell capable of effector function. During development, multipotential haemopoietic stem cells (HSC) can undergo quiescence, programmed cell death, self-renewal or differentiation. The first stage of HSC differentiation is a loss of the cell's ability to self-renew; this is followed by commitment to either the lymphoid or myeloid lineages, which become more restricted until the cells form functionally distinct mature blood cells. 1 Some studies demonstrate that once progenitor cells commit to a particular lineage, distinct gene expression patterns are maintained by transcription factors to determine the phenotype of the cell and ensure that cells are unable to change their fate decisions. 2 Environmental stimuli may also play a role in determining the differentiation pathways that HSC follow. 3 Under some circumstances, the normal program of HSC differentiation can be disrupted. Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of HSC that results in the expansion and release of immature progenitor cells from the bone marrow. The tyrosine kinase inhibitor, imatinib (also known as STI-571 or Glivec), is a 2-phenylaminopyrimidine derivative that has been reported to inhibit specifically the growth of bcr-abl expressing CML progenitors without affecting the survival and growth of normal cells. 4, 5 It functions as a potent ATP-competitive inhibitor of the abl protein kinase, inhibiting the kinase activity of bcr-abl and specifically inhibiting the growth of leukaemic cells. 6 Therapeutic doses of imatinib are also sufficient to inhibit the c-abl, platelet-derived growth factor receptor (PDGFRB) and c-kit tyrosine kinases with a similar potency, suggesting that imatinib may also have clinical activity against tumours and nonmalignant proliferative disorders that involve deregulated PDGFRB and c-kit signalling. 5, 7 Screening of other related members of the type III receptor kinase family, such as c-fms, Flt-1 and Flt-3 demonstrated that these kinases are not affected by imatinib, suggesting that their ATP-binding domains are sufficiently different to have a lower affinity for imatinib.
Initial in vitro studies have suggested that imatinib has a negligible effect on normal haemopoiesis, and in vivo, a phase 1 study in CML patients demonstrated that a haematologic response with minimal toxic effects could be achieved with a dose of 300 mg of imatinib. 8 A subsequent phase 2 study demonstrated that 18% of patients displayed adverse events that were related to treatment when the imatinib dose was increased to 400 or 600 mg. 9 These events included cytopenias such as neutropenia and thrombocytopenia, and were attributed to the pharmacological effect of imatinib on leukaemic cells and the lack of bone marrow reserve in patients. 9 The possibility that imatinib-induced cytopenias arise due to a suppression of normal myelopoiesis has not yet been explored. Here, we show that imatinib affects normal haemopoiesis by inhibiting the in vitro development and maturation of monocytes/macrophages.
Materials and methods

Preparation of bone marrow mononuclear cells
Normal bone marrow (BM) was aspirated into preservative-free, sodium heparin-containing tubes (1 000 U/ml; Fisons Pharmaceuticals, Homebush, NSW, Australia), from the sternum and posterior iliac crest of healthy volunteers following informed consent. The Human Ethics Committee, Royal Adelaide Hospital approved the use of normal BM cells for these studies. Alternatively, BMMNCs were washed twice with HBSS/2% BSA (Sigma) prior to the addition of anti-CD34 Dynabeads (Dynal, Oslo, Sweden) at a 1:1 ratio of beads:cells. This suspension was incubated on a rotator for 60 min at 41C. Cells rosetted by the CD34 Dynabeads were purified by multiple rounds of capture and washing using a cobalt-samarium magnet (MPC-1, Dynal), until no free cells remained. The CD34 + cells were then recovered by incubating the cell-bead complexes in DETACHaBEAD TM reagent (Dynal) according to the manufacturer's recommendation. The released CD34 + cells were washed several times in HBSS/2% BSA and a portion labelled with HPCA-2-PE (as described above) in order to assess purity. In all experiments, this procedure yielded CD34 + populations that were 490% pure.
Haemopoietic colony assays
BMMNCs or CD34 + cells were assayed for their ability to form colonies in semisolid agar, based on a modification of a method previously described by Johnson. 10 Briefly, colony cultures were established in triplicate by plating 5.0 Â 10 4 BMMNC, or 7.5 Â 10 3 CD34 + cells, per 35 mm cell culture dish (Falcon), in 1.0 ml of IMDM supplemented with 0.33% agar (Bacto TM Agar, Difco), 25% FCS and 2 mM L-glutamine. Colony growth was stimulated by the addition of M-CSF (10 ng/ml) or GM-CSF (10 ng/ml), or a combination of two growth factors (GM-CSF (10 ng/ml), M-CSF (10 ng/ml)), four growth factors (IL-3, IL-6, G-CSF, GM-CSF at 10 ng/ml) or five growth factors (IL-3, IL-6, G-CSF, GM-CSF, SCF at 10 ng/ml) (Peprotech). Imatinib (Novartis, Basel, Switzerland) was also added to cultures in triplicate, to a final concentration ranging from 0 to 50.0 mM. Control cultures with no added growth factors or no added imatinib were also included in all experiments.
Cultures were incubated in a humidified chamber at 371C+5% CO 2 for a period of 2 weeks, after which time they were fixed overnight at 41C in 1.0 ml of 3% glutaraldehyde. Fixed agar cultures were rinsed with phosphate-buffered saline, transferred to glass slides and dried down using nitrocellulose paper. These slides were sequentially stained for naphthol acetate esterase 11 and chloroacetate esterase, 12 and stained with luxol fast blue dye (BDH), 13 to identify monocyte/ macrophage, neutrophil and eosinophil colonies, respectively. Slides were then enumerated for each of the colony types, with all colonies, being scored according to standard criteria (450 cells).
CD34
+ liquid culture assays CD34 + cells were isolated from BMMNC using Dynabead magnetic separation, as described previously, and incubated in a serum-deprived medium (SDM; IMDM/1% BSA supplemented with 2 mM L-glutamine, 200 mg/ml transferrin, 10 mg/ml insulin (Actrapid s , Novo Nordisk, Australia), 10 À4 M b-mercaptoethanol, 50 mg/ml low-density lipoproteins (Sigma)) at a final concentration of 5.0 Â 10 3 /ml. IL-3, IL-6, G-CSF and GM-CSF were added to a final concentration of 10 ng/ml (Peprotech). T25 cell culture flasks (Cellstar s , Greiner bio-one, Germany) were seeded with a 5.0 ml volume of cell suspension, and imatinib was added to appropriate flasks (in duplicate) to a final concentration ranging from 0 to 30.0 mM. Cells were refed with growth factors (to a final concentration of 10 ng/ml) after 7 days, and supplemented with 15.0 ml additional medium after 14 days, according to a modification of the method by Haylock et al.
14 Cells remained in culture at 371C+5% CO 2 for a period of 21 days, and viability was assessed at weekly intervals using trypan blue exclusion.
After 21 days, cultures were assayed for cell count and viability (using trypan blue exclusion). Cytospin preparations were examined following Jenner-Giemsa staining and Esterase staining, and cells were phenotyped by flow cytometry using directly conjugated antibodies against CD14 (FITC), CD34 (PE), CD11c (PE), CD33 (PE) and HLA-DR (PE) (Becton Dickinson, Mountain View, CA, USA). A measure of 10 ml of each antibody was used per 10 6 cells, and cells were incubated on ice for a period of 45 min. Cells were washed twice with HHF prior to analysis on a Coulter Elite flow cytometer.
Monocyte cultures
Buffy coats from normal healthy volunteers were obtained from the Australian Red Cross Blood Service, Adelaide, with ethical approval, and mononuclear cells were collected by centrifugation over Ficoll-Hypaque at 400 g for 30 min. Mononuclear cells were further enriched for monocytes using counter-current elutriation. 15 The purity of monocytes following the isolation procedure was calculated by staining with an anti-CD14-PE (Beckton Dickinson) antibody for 45 min on ice, and was routinely greater than 85%.
Monocytes were resuspended in SDM to a final concentration of 1.0 Â 10 5 cells/ml, and supplemented with rh-M-CSF (40 ng/ml) or rh-GM-CSF (20 ng/ml) (Peprotech). A measure of 1.0 ml volumes of cell suspension were transferred to wells of a 24-well cell culture plate, and imatinib was added to duplicate wells at a concentration ranging from 0 to 30.0 mM. Cultures were incubated in a humidified chamber at 371C+5% CO 2 .
After a period of 7 days, cultures were examined for changes in cell morphology (increase in cell size, formation of pseudopodia), and the degree of adherence. Cells were detached from culture plates by removing the supernatant and incubating the cells in trypsin (Sigma) for 5 min at 371C. The trypsin activity was neutralised by the addition of HHF, and cells were then detached by vigorous pipetting. The maturity of cells in these cultures was examined by flow cytometric analysis of cell suspensions following staining with antibodies directed against CD14 (PE), HLA-DR (PE), CD11c (PE) (Becton Dickinson) and Carboxypeptidase M (MAX.1, mouse IgG supernatant: generously donated by R Andreesen, Department of Haematology and Oncology, University of Regensburg, Germany).
Permanox s chamber slide (Lab-Tek s , Nalge Nunc International, USA) cultures were also established as described above, and at the conclusion of the culture period the cells were fixed for 15 min in 3% glutaraldehyde and examined following staining for naphthol acetate esterase.
Statistics
To determine whether differences between groups were statistically significant, the data were analysed using ANOVA. Differences were considered to be statistically significant when the probability value was o0.05. All results are representative of at least three individual experiments.
Results
Treatment of normal haemopoietic progenitor cells with imatinib is associated with inhibition of monocyte/ macrophage colony formation
We first evaluated the effect of imatinib on normal haemopoiesis in semisolid agar colony assays stimulated with either 4HGF (IL-3, IL-6, G-CSF, GM-CSF) or 5HGF (IL-3, IL-6, G-CSF, GM-CSF, SCF), as shown in Figure 1 . In the absence of imatinib, a 5HGF combination yielded twice as many colonies as a 4HGF combination (Figure 1a) . When 4HGF was used to stimulate colony growth, colony formation was reduced by 50% at concentrations of imatinib of 3.0 mM or greater, compared to control cultures (Figure 1a ). On addition of imatinib to cultures stimulated with 5HGF, colony formation at each of the imatinib concentrations mirrored the profile achieved using 4HGF, demonstrating the known effect of imatinib in blocking the SCF receptor, c-kit (Figure 1a) .
To examine the effect of imatinib on the formation of specific types of colonies, differential esterase staining was used. Monocyte/macrophage growth was impaired by concentrations of imatinib used therapeutically, with a 59% reduction in monocyte/macrophage growth at a concentration of 1.5 mM imatinib, when either a 4HGF or 5HGF stimulus was used (Figure 1b) . Growth was further reduced using 3.0 mM imatinib, and, at concentrations of imatinib greater than or equal to 30.0 mM, no colony growth was observed. In the presence of 5HGF, imatinib reduced the formation of neutrophil and eosinophil colonies to the level observed with 4HGF (Figure 1c and d) . The growth of eosinophil colonies was not affected by imatinib until the concentration was greater or equal to 15.0 mM (Figure 1c) , while the effect of imatinib on neutrophil colonies was inconsistent between 3.0 and 10.0 mM. Specifically, a 44% reduction in neutrophil colony growth was observed at 3.0 mM using a 4HGF stimulus, and a 70% reduction at 5.0 mM was observed using a 5HGF stimulus (Figure 1d ). The overall inhibition of neutrophil growth was less significant than that observed for monocyte/macrophage colonies.
Purification Haemopoietic colony assays using normal bone marrow progenitor cells. The addition of imatinib to cultures decreased total colony number (a) and monocyte/macrophage colonies (b) following stimulation with either 5HGF (IL-3, IL-6, G-CSF, GM-CSF, SCF) (black columns) or 4HGF (IL-3, IL-6, G-CSF, GM-CSF) (white columns). Eosinophil colonies (c) were not affected until 15.0 mM imatinib, and neutrophil colonies (d) were slightly affected at concentrations of 3.0 mM and greater. The 5HGF control was used to set the value for maximal growth, and all other data points were normalised to this value. Results represent normalised data from three individual experiments using different donors (*denotes Po0.05).
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number of monocyte/macrophage colonies when compared to colonies stimulated with 4HGF, with an average of 111 monocyte/macrophage colonies per plate vs an average of 25 monocyte/macrophage colonies per plate. The addition of 0.3 mM imatinib to these cultures decreased monocyte/macrophage growth by 40%, and this inhibition increased to 80% at 3.0 mM imatinib (Figure 2a) . On increasing the concentration of imatinib to 10.0 mM, almost no monocyte/macrophage growth was observed. The combination of GM-CSF and M-CSF also enhanced eosinophil colony formation compared to 4HGF stimulus, and was found to be unaffected by imatinib until the concentration of imatinib was 10.0 mM or greater (Figure 2b) .
The use of GM-CSF or M-CSF alone confirmed that growth of monocyte/macrophage colonies was significantly inhibited at low concentrations of imatinib (1.0 mM) (Figure 3) . While the degree of imatinib inhibition was more significant for cultures stimulated with M-CSF, on addition of 5.0 mM imatinib, monocyte/macrophage growth was minimal following both GM-CSF and M-CSF stimulation (Figure 3) .
Imatinib inhibits the proliferation of normal CD34 + cells in liquid culture
To evaluate and confirm the effect of imatinib on normal haemopoiesis, and to help determine the stage at which imatinib inhibited monocyte/macrophage differentiation, liquid cultures were established. CD34 + progenitor cells were grown for 3 weeks in SDM supplemented with 4HGF and imatinib, and at the conclusion of the culture, cells were enumerated, phenotyped and assessed for viability.
Over a 3-week culture period, a 22-fold expansion in cell yield was observed under control conditions. A 25% reduction in cell yield was observed when 0.3 mM imatinib was present for the duration of culture, and the extent of inhibition was more pronounced at higher concentrations of imatinib (Figure 4a) . Specifically, at 5.0 mM imatinib the cell yield was 70% lower than control cultures, and at 30.0 mM imatinib, the cell number was below the seeded level. A reduction in cell viability was only seen at 30 mM imatinib, where viability was reduced from 80 to 60% (Figure 4b) .
To determine whether a phenotypically distinct cell type was selectively inhibited by imatinib, bulk cell cultures were phenotyped for the expression of CD11c, CD14, CD33 and CD34. Despite the reduction in cell numbers associated with an increase in the concentration of imatinib (Figure 4a ), no definitive differences in the percentage of cells expressing CD11c, CD14 and CD33 was noted until the concentration of imatinib was 5.0 mM or greater (Figure 4c ). The percentage of cells expressing CD14 and CD33 was reduced by 41 and 56%, respectively, at 5.0 mM imatinib, while the proportion of cells expressing CD11c was less affected by imatinib treatment, with a 43% reduction at 10.0 mM imatinib. After 3 weeks of culture, CD34 expression was not observed (Figure 4c ), indicating that some degree of maturation had occurred. An analysis of Jenner-Giemsa-stained cytospin preparations demonstrated that the majority of cells in all cultures were morphologically immature and consisted of immature myeloid cells (data not shown).
Imatinib inhibits the differentiation of monocytes into macrophages in vitro
To determine whether imatinib inhibits the differentiation of monocytes into macrophages, monocyte cultures were supplemented with M-CSF or GM-CSF in the presence or absence of imatinib. After 7 days of culture, the morphology and phenotype of cells were examined.
In control cultures stimulated with M-CSF, cells morphologically resembled macrophages, as characterised by an increase Haemopoietic colony assays using normal CD34 + progenitor cells, stimulated with a combination of M-CSF and GM-CSF. The addition of imatinib to cultures decreased the number of monocyte/macrophage colonies (a), and eosinophil colonies (b) were affected at concentrations of 10 mM or greater. Control cultures with no imatinib were used to set the value for maximal growth, and all other data points were normalised to this value. Results represent normalised data from three individual experiments using different donors (*denotes Po0.05). Monocyte/macrophage growth in haemopoietic colony assays using normal CD34 + progenitors, stimulated with either M-CSF (black columns) or GM-CSF (white columns). Monocyte/macrophage growth was affected at 0.3 mM imatinib, and minimal growth was observed at 5.0 mM imatinib or greater. Control cultures with no imatinib were used to set the value for maximal growth, and all other data points were normalised to this value. Results represent normalised data from three individual experiments using different donors (*denotes Po0.05).
in cell size and the formation of pseudopodia (Figure 5a) . A similar morphological differentiation was also observed in monocyte cultures stimulated with GM-CSF; however, this differentiation was more pronounced based on the extent of pseudopodia formation, and was evident after a shorter period of time in culture (Figure 5a ). The addition of imatinib to cultures stimulated with either M-CSF or GM-CSF significantly decreased the proportion of cells displaying macrophage morphology, and this was evident at concentrations of imatinib as low as 1.0 mM (Figure 5a) . A decrease in cell viability was not responsible for this result, as viability was consistently 75% over the range of imatinib concentrations used (data not shown).
A phenotypic analysis of cultured cells confirmed the transition of monocytes into macrophages following a 7-day culture period, based on a 12-fold increase in the binding of an antibody that detects Carboxypeptidase M (Max.1), 16 when compared to time 0 (data not shown). A comparison of Carboxypeptidase M expression was also made after culture of monocytes with imatinib for 7 days, to examine phenotypically the effect of imatinib on the differentiation of monocytes into macrophages (Figure 5b) . No significant change in the expression of Carboxypeptidase M was observed until the concentration of imatinib reached 5.0 mM, when expression was 50% of control values. This was observed for cells stimulated with both M-CSF and GM-CSF, and suggests that the effect of imatinib on the differentiation of monocytes into macrophage is more apparent morphologically than immunophenotypically.
Cells cultured in the presence of GM-CSF or M-CSF were also assessed for changes in the expression of HLA-DR, CD11c and CD14 (Figure 5b 
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(data not shown), while CD11c expression was reduced by 30-50% at concentrations of imatinib of 5.0 mM and above. The intensity of CD14 expression on cells stimulated with M-CSF was reduced by 30% at 1.0 mM imatinib and 70% at 5.0 mM imatinib. Monocytes stimulated with GM-CSF, however, did not express CD14. Since detachment of cells from the culture plates in these experiments required trypsinisation, initial experiments were carried out to confirm that cleavage of the surface markers of interest did not occur.
Discussion
Previous studies have reported that normal haemopoiesis is moderately reduced in clonogenic assays following treatment with imatinib. 17, 18 The reduction in colony formation was found in cells of the erythroid lineage; however, granulocyte/macrophage colonies were reported to be unaffected at concentrations of imatinib below 10.0 mM. 17 Here, we demonstrate a clear effect of imatinib on normal haemopoiesis involving cells of the monocyte/macrophage lineage, at concentrations of imatinib achieved therapeutically.
The use of semisolid agar cultures enabled analysis of the impact of imatinib on haemopoietic development. Initial cultures were stimulated with 4HGF or 5HGF, to drive the proliferation of cells along the granulocyte/macrophage lineages.
14 The growthenhancing effects of SCF were completely abrogated in the presence of 0.3 mM imatinib, supporting the hypothesis that signal transduction through c-kit is inhibited by imatinib. 5, 7 The low level of imatinib required to inhibit c-kit phosphorylation completely was consistent with results from Buchdunger et al, Effect of imatinib on the differentiation of peripheral blood monocytes into macrophages. Naphthol acetate esterase staining demonstrated that imatinib decreased the ability of monocytes to differentiate into macrophages based on morphologic properties (a) (taken under a Â 10 magnification lens). Flow cytometric analysis of surface expression of CD14, CD11c, HLA-DR and Carboxypeptidase M demonstrated a reduction in cell maturity at concentrations of imatinib greater than and equal to 5.0 mM (values represent mean fluorescent intensities) (b). Results are representative of data from three individual experiments using different donors.
In the absence of SCF, the effect of imatinib on colony growth was significant at levels of 3.0 mM and above, suggesting that abrogation of signalling through tyrosine kinases other than c-kit may be occurring. However, the contribution of exogenous SCF and/or an upregulation in c-kit expression cannot be ruled out. If an effect due to autocrine SCF production was occurring in this system, it would only account for the difference in cell growth observed between the control and 0.3 mM groups, and not any differences observed at concentrations of imatinib above 0.3 mM. Furthermore, conflicting data have been published concerning the effect of GM-CSF on the expression of c-kit, as reports have been presented of both an upregulation and downregulation in c-kit expression following GM-CSF stimulation. 19, 20 Given that complete inhibition of exogenous SCF was observed at the lowest concentration of imatinib used, it is unlikely that an increase in c-kit expression as a result of GM-CSF stimulation is responsible for the inhibitory effect of imatinib observed in this study.
Inhibition of the PDGFRB by imatinib has also been reported, with an IC 50 value of approximately 0.1 mM.
7 PDGF was initially identified as a potent mitogen for mesenchymal cells, and PDGF signalling is critical in embryological development and in the pathogenesis of proliferative disease in adults (for review, see Rosenkranz and Kazlauskas 21 ). HSC, however, have been reported to fail to respond directly to PDGF. Little evidence for the expression of PDGFRB by HSC has been reported, although RNA expression has been shown on normal marrow macrophages. 22 Further investigations would be required to address fully the possibility that inhibition of PDGFRB by imatinib is involved in the abrogation of monocyte/macrophage growth and differentiation in this study.
ABL-related gene (ARG) and c-abl are two other tyrosine kinases known to be selectively inhibited by imatinib. 23, 24 The function of abl tyrosine kinase is not fully understood; however, it is thought to be important in cell growth and arrest, the modulation of apoptosis and DNA repair (for review, see Shaul 25 ). While abl knockout mice have decreased neonatal viability and lymphopenia, there is no direct evidence of a role for abl in haemopoietic proliferation. 4 ARG is widely expressed, although this molecule only appears to be important in the central nervous system, and is not involved in normal haemopoiesis. 24 As the IC 50 value for c-abl is between 0.025 and 0.25 mM, 4 and ARG has a similar sensitivity to imatinib, 24 it is unlikely that inhibition of c-abl or ARG by imatinib accounts for the growth inhibition observed in this study.
While c-fms belongs to the same family of tyrosine kinases as c-abl, c-kit and PDGFRB, published data have demonstrated that imatinib does not affect the tyrosine phosphorylation of c-fms up to a concentration of 10 mM. 7 The concentration of imatinib required to inhibit c-fms phosphorylation was not determined in that study, suggesting that the IC 50 value for c-fms is in excess of 10 mM. This observation is supported by our results, as a similar profile of imatinib-induced growth inhibition was observed when different growth factor combinations, with and without M-CSF, were used to stimulate colony growth. Here, we observe an inhibition of monocyte/macrophage growth at concentrations of imatinib as low as 0.3 mM, which is far below the level at which c-fms was reported to be unaffected. 7 Eosinophil growth remained unaffected until higher levels of imatinib were attained, and neutrophil colonies demonstrated inconsistent inhibition between 3.0 and 10.0 mM imatinib. This supports other studies, 7 which demonstrate that imatinib does not affect the phosphorylation of c-fms, and argues against imatinib-specific inhibition of the M-CSF signal transduction pathway.
The negative effect of imatinib on colony formation might be explained either by cell death or an inhibition of proliferation. A liquid bulk culture assay was therefore established using CD34 + progenitor cells to confirm the inhibition of monocyte/macrophage growth and to examine the effect of imatinib on cell viability. Even at concentrations of 10.0 mM, where toxicity may be expected to result in cell death, 80% of cells remained viable. This suggests that inhibition of cell division occurred in the presence of imatinib, rather than an increase in cell death. The possibility that cell death occurred subsequent to cell division cannot be discounted; however, total cell yield demonstrated that at least the seeded cell number was recovered from all cultures, with the exception of 30 mM imatinib. Investigations into the kinetics of both proliferation and survival are ongoing.
While imatinib significantly inhibited the proliferation of CD34 + cells in liquid culture, the ability of imatinib to inhibit cell maturation was less striking than that observed in semisolid agar cultures. This was attributed to the cells in liquid culture only undergoing partial maturation. Failure of the cells to undergo differentiation equivalent to that observed in the semisolid cultures may be due to the absence of foetal calf serum from the growth medium. However, it is clear from cell count and viability studies in the liquid culture assay that there is a generalised suppression of myeloid growth at concentrations of imatinib as low as 0.3 mM.
Neither the semisolid culture assay nor the liquid culture assay revealed whether there was any impediment in monocyte to macrophage differentiation in the presence of imatinib. Peripheral blood monocytes placed in culture differentiate into cells that display tissue macrophage-like characteristics, and it is thought that this process parallels the process of differentiation that occurs in vivo. 26 This principle was therefore applied to examine the effect of imatinib on the differentiation of monocytes into macrophages.
Both GM-CSF or M-CSF induced the differentiation of monocytes into macrophages; however, these macrophages differed with respect to morphology and cell surface phenotype, consistent with results from Young et al. 27 GM-CSF and M-CSF led to similar levels of expression of HLA-DR and CD11c on macrophages, although the expression of CD14 was higher on macrophages derived from culture with M-CSF than GM-CSF. The influence of GM-CSF and M-CSF on CD14 expression, as well as its modulation during monocyte differentiation appears to depend on multiple factors including adherence, length of time in culture and the growth factors used. 26, 28 CD14 expression on M-CSF stimulated monocytes was significantly reduced following the addition of imatinib to cultures. Furthermore, there was a concomitant decrease in Carboxypeptidase M expression, which was consistent with a decrease in macrophage differentiation based on morphologic criteria, suggesting that the cells remaining in culture were immature. Functional studies may clarify this. Imatinib also resulted in a loss of morphologic and phenotypic characteristics in GM-CSF stimulated cultures, suggesting that blockade of c-fms does not account for the imatinib-mediated effect.
Although CML patients treated with imatinib can exhibit cytopenia, there does not appear to be specific suppression of the monocytic lineage, which is in contrast to our findings in vitro. Haemopoiesis in CML patients treated with imatinib, however, is not truly 'normal' as the haemopoietic system is in a state of recovery following the elimination of leukaemic cells.
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Furthermore, imatinib does not inhibit syngeneic bone marrow engraftment and postirradiation haemopoietic recovery in a murine model. 29 In addition, the in vivo effect of imatinib on cells of the monocyte/macrophage lineage is difficult to assess due to the short transient time that the monocytes spend in the blood, and the location of macrophages in the tissues. It will be interesting to observe whether long-term administration of imatinib to CML patients will have implications for altered or depressed immune function as a consequence of a suppressive action of this drug on cells of the monocyte/macrophage lineage.
In conclusion, this study has demonstrated that imatinib inhibits the formation of monocyte/macrophage colonies from normal bone marrow progenitor cells, and abrogates the differentiation of monocytes into macrophages. While liquid culture assays did not reveal a specific inhibition of differentiation along the monocytic lineage because of limited cell maturation, there was a general suppression of cell growth that was not due to a decrease in cell viability. C-abl 4 and PDGFRB 21 do not appear to play an important role in haemopoietic proliferation and differentiation, and inhibition of monocyte/macrophage growth and differentiation occurred in the absence of exogenous SCF, implying that inhibition of c-abl, PDGFRB and c-kit by imatinib alone does not account for these results. The precise stage at which imatinib is inhibiting the growth of monocytes/macrophages remains to be defined, as does the ability to activate macrophages following imatinib treatment. Studies to address these issues are currently underway. The results from this study suggest that imatinib inhibits undefined tyrosine kinase(s) involved in monocyte/macrophage development and differentiation. These results raise the possibility of using imatinib, or its derivatives, for the treatment of chronic diseases with monocyte/macrophage involvement, such as rheumatoid arthritis.
